Aflac (AFL) Set to Announce Earnings on Wednesday

Aflac (NYSE:AFL) is scheduled to release its earnings data after the market closes on Wednesday, May 1st. Analysts expect Aflac to post earnings of $1.58 per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Aflac (NYSE:AFL) last issued its quarterly earnings data on Thursday, February 1st. The financial services provider reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.22). The firm had revenue of $3.78 billion for the quarter, compared to analyst estimates of $4.44 billion. Aflac had a return on equity of 17.59% and a net margin of 24.92%. During the same period in the previous year, the business earned $1.29 EPS. On average, analysts expect Aflac to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Aflac Price Performance

Shares of NYSE AFL opened at $83.61 on Monday. The stock has a market capitalization of $48.11 billion, a price-to-earnings ratio of 10.79, a PEG ratio of 2.29 and a beta of 0.91. Aflac has a 12 month low of $64.10 and a 12 month high of $86.26. The firm’s 50 day simple moving average is $82.69 and its 200-day simple moving average is $81.78. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.06 and a quick ratio of 0.06.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Evercore ISI lowered Aflac from an “in-line” rating to an “underperform” rating and lifted their price target for the stock from $76.00 to $78.00 in a report on Thursday, January 4th. The Goldman Sachs Group boosted their price objective on shares of Aflac from $61.00 to $75.00 and gave the company a “sell” rating in a report on Tuesday, January 9th. Piper Sandler boosted their price objective on shares of Aflac from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, April 5th. Raymond James boosted their price objective on shares of Aflac from $83.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Finally, Keefe, Bruyette & Woods boosted their price objective on shares of Aflac from $83.00 to $87.00 and gave the company a “market perform” rating in a report on Wednesday, April 10th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $82.15.

Insiders Place Their Bets

In other news, Director Masatoshi Koide sold 30,493 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the sale, the director now owns 86,090 shares of the company’s stock, valued at approximately $6,879,451.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Masatoshi Koide sold 30,493 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $79.91, for a total transaction of $2,436,695.63. Following the sale, the director now owns 86,090 shares of the company’s stock, valued at $6,879,451.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Arthur Reginald Collins sold 3,000 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $79.73, for a total value of $239,190.00. Following the completion of the sale, the director now directly owns 5,592 shares in the company, valued at $445,850.16. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,493 shares of company stock worth $3,765,706. Corporate insiders own 0.90% of the company’s stock.

Aflac Company Profile

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.